Clinical trials: Non-communicable Diseases
Hepatitis C Virus Infection
Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
The primary objectives of the study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (Vosevi®; SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks and of…
- Trial name
- POLARIS-4 (NCT02639247)
- Testing
- SOF/VEL/VOX, SOF/VEL
- Where
- 78 sites in United States, Australia and 6 more
- Volunteers
- 333 people
- Sponsor
- Gilead Sciences
Lymphoma, Non-Hodgkin, HIV Infections
A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic…
- Trial name
- NCT00002284
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
Hepatitis C, Chronic
An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
This is an extension study of HCV-05-002. The objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for an additional 36 weeks in patients with chronic…
- Trial name
- NCT00292084
- Testing
- Celgosivir
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- BioWest Therapeutics Inc
Meningitis, Cryptococcal, HIV Infections
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients.
- Trial name
- NCT00002040
- Testing
- Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
HIV Infections
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give a new anti-HIV drug combination to HIV-infected patients who have never taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) and who have failed to…
- Trial name
- NCT00002418
- Testing
- Emivirine, Hydroxyurea, Nevirapine
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
Candidiasis, Oral, HIV Infections
A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole
To provide maintenance treatment with itraconazole solution for patients who were clinical responders in the ITR-USA-94 protocol, even if they subsequently relapsed.
- Trial name
- NCT00002341
- Testing
- Itraconazole
- Where
- United States
- Sponsor
- Janssen, LP
Hepatitis C, Chronic
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C genotype 1.
- Trial name
- NCT01508130
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 672 people
- Sponsor
- Hoffmann-La Roche
H1N1 Influenza Virus, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Trial name
- NCT01032408
- Testing
- Focetria®, Begrivac®
- Where
- 2 sites in Brazil
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
COVID-19 Infection
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting.
- Trial name
- CRISIS2 (NCT04575038)
- Testing
- Brequinar
- Where
- 14 sites in United States
- Volunteers
- 115 people
- Sponsor
- Clear Creek Bio, Inc.
Candidiasis
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
Candida is the most common fungal pathogen identified in hospitalized patients. This study will seek to enroll adult patients (18 years of age or older) with invasive Candida infections (involving deep tissues and organs).
- Trial name
- NCT00083343
- Testing
- MK0991, caspofungin acetate/Duration of Treatment: variable
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Hemophilia A
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
In this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the…
- Trial name
- NCT03588299
- Testing
- BAY2599023 (DTX201)
- Where
- 13 sites in United States, Bulgaria and 4 more
- Volunteers
- 11 people
- Sponsor
- Bayer
Respiratory Disorders
Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine
This study will provide information regarding the sequential administration of two vaccines adjuvanted with AS01. The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when administered…
- Trial name
- NCT03894969
- Testing
- GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E, Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
- Where
- 14 sites in Estonia, Finland and 3 more
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Abscess, Intra-Abdominal, Cholecystitis
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.
The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary…
- Conditions
- Abscess, Intra-Abdominal, Cholecystitis, Wound Infections, Peritonitis
- Trial name
- NCT00463762
- Testing
- CP-75385-02 Cefoperazone/sulbactam
- Sponsor
- Pfizer
COVID-19, SARS-CoV-2 Infection
Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has negatively impacted global health and requires more research to develop better tests and to improve disease treatment.
- Trial name
- SARS-CoV-2 (NCT04465981)
- Testing
- Sampling
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- INanoBio Inc.
Lung Cancer, Small Cell Lung Cancer
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
- Trial name
- NCT05337163
- Testing
- Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination
- Where
- China
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
This is a sequential Phase I and IIa study to identify the maximum tolerated dose and to evaluate safety, tolerability, toxicity, pharmacokinetics and pharmacodynamics of the oral sphingosine kinase inhibitor ABC294640…
- Trial name
- ABC-102 (NCT02229981)
- Testing
- ABC294640
- Where
- United States
- Sponsor
- RedHill Biopharma Limited
Cytomegalovirus (CMV)
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants.
- Trial name
- MARIBEL (NCT06677892)
- Testing
- No Intervention
- Where
- 9 sites in Belgium
- Volunteers
- 66 people
- Sponsor
- Takeda
Skin Infections, Bacterial
ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
This is an open label, multi-centre, non-interventional post-marketing surveillance.
- Trial name
- ALTARGOPMS (NCT01445600)
- Testing
- ALTARGO(retapamulin)
- Where
- South Korea
- Volunteers
- 3,612 people
- Sponsor
- GlaxoSmithKline
Influenza, Acute Upper Respiratory Infection
Treatment of Influenza in Routine Clinical Practice
This study evaluates the statistics of influenza and acute respiratory viral infections (ARVI) management in outpatient sites in Russia, Armenia, Moldova and Georgia (epidemiology: disease severity and bacterial exacerbations…
- Trial name
- FLU-EE (NCT02983019)
- Testing
- Kagocel
- Where
- 4 sites in Armenia, Georgia and 2 more
- Volunteers
- 18,946 people
- Sponsor
- Nearmedic Plus LLC
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.